In the current climate of global uncertainty and shifting market dynamics, companies are forced to make challenging strategic decisions. Renowned genetic testing firm 23andMe recently found itself in the spotlight after filing for bankruptcy protection under Chapter 11—a pivotal step aimed at facilitating the sale of the business for approximately 50 million dollars.